Enhanced Outcome with Silodosin

Silodosin has 583-fold higher selectivity for the alpha-1A subtype than alpha-1B subtype, thus is more uroselective than tamsulosin. Silodosin improves symptoms of BPH from the early stage of administration, both in new patients and those who have previously received tamsulosin.